Clinical trials: Meningococcal Meningitis
Epidemic Meningitis
A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)
This study included 180 trial participants who had previously taken part in the Phase IIIb clinical trial of the ACYW135 group meningococcal polysaccharide-conjugated vaccine (CRM197 carrier) for children aged 4-6 years (Protocol…
- Trial name
- NCT07743411
- Testing
- Previously vaccinated with MCV4 (CanSino), Previously vaccinated with MPSV4 (LvZhu)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningococcal Meningitis, Measles
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers.
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00422292
- Testing
- Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,664 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Sero-type C Infection
Evaluation of Meningococcal C Vaccine Programmes in Canadian Children
The purpose of the study is to see which of the three current provincial Meningococcal C Conjugate vaccine schedules in Canada provide the longest lasting protection against Meningococcal C disease and to see if a booster…
- Trial name
- NCT00936962
- Testing
- NeisVac C vaccine (12mth)
- Where
- 3 sites in Canada
- Volunteers
- 452 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Meningitis, Meningococcemia
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
This study was designed to generate data for the assessment of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) when given to adults aged 18 to 55 years.
- Trial name
- NCT00772629
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Meningococcal
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single…
- Trial name
- NCT02986854
- Testing
- Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 704 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of Meninggococcal (A,C,Y and W135) Conjugate Vaccine in 2 months to 6 years-old children.
- Trial name
- NCT02003495
- Testing
- MCV-ACYW135 Vaccine Group, MPV-ACYW135 Vaccine Group, MPV-A Vaccine Group
- Where
- China
- Volunteers
- 2,195 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Meningococcal Meningitis
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
The purpose of this study was to explore the safety and immunogenicity of the experimental vaccine compared with the control vaccines.
- Trial name
- NCT06337071
- Testing
- ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Meningitis, Meningococcal Meningitis
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers
The purpose of the study was to evaluate the immunogenicity and describe the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed…
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02955797
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
- Where
- 33 sites in Finland, Germany and 2 more
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Meningitis
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
The aim of the study was to describe the safety and antibody response to booster administration with Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine in participants who received…
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02752906
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Meningococcal
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.
- Trial name
- NCT04318548
- Testing
- Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
- Where
- 53 sites in United States, Italy
- Volunteers
- 945 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcemia
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose…
- Conditions
- Meningitis, Meningococcemia, Neisseria Meningitidis
- Trial name
- NCT00772070
- Testing
- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- Where
- 8 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal Meningitis
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea
The purpose of the study is to perform the re-examination of Menactra® administered in the routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation.
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02864927
- Testing
- Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- South Korea
- Volunteers
- 1,311 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Primary objective: This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared…
- Trial name
- NCT03547271
- Testing
- MenACYW conjugate vaccine, Meningococcal group A, C, W-135, and Y conjugate vaccine, DTaP-IPV-HB-Hib vaccine
- Where
- 33 sites in Czechia, Finland and 5 more
- Volunteers
- 1,660 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
Evaluate the effectiveness of 2 doses of MenABCWY vaccine in adolescents compared to a single dose of MenACWY vaccine.
- Trial name
- NCT02140762
- Testing
- MenABCWY, MenACWY
- Where
- 8 sites in United States
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
High and Low Resource Interventions to Promote HPV Vaccines
Human Papillomavirus (HPV) is a significant public health issue affecting nearly 14 million people in the United States. HPV can lead to cervical, oropharyngeal, anal, and penile cancers as well as genital warts.The purpose of…
- Conditions
- Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication
- Trial name
- NCT03824093
- Testing
- AFIX Only, AFIX+ Provider Communication Training
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Meningitis, Meningococcal
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.
- Trial name
- NCT00474526
- Testing
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib
- Where
- 63 sites in United States, Argentina and 1 more
- Volunteers
- 4,545 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prevention of Meningococcal Infection
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age
- Trial name
- NCT00310674
- Testing
- Meningococcal C Conjugate Vaccine
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningitis
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
The purpose of this double-blind study is to evaluate the safety, reactogenicity and immunogenicity of Group A,C,Y and W135 Meningococcal Polysaccharide Vaccine in 2 to 30 years-old Children and Adults.
- Trial name
- NCT02003313
- Testing
- Group T, Group C
- Where
- China
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Meningococcal Disease
Safety of MenACWY-CRM Vaccination in Adolescents
The purpose of this US FDA post-marketing commitment study is to evaluate the safety of MenACWY-CRM among 50.000 vaccinated adolescents within a large US Healthcare Maintenance Organization who received MenACWY-CRM vaccination as…
- Trial name
- NCT01452464
- Testing
- MenACWY-CRM
- Where
- 3 sites in United States
- Volunteers
- 55,397 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infections, Meningitis
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier
- Trial name
- NCT00862277
- Testing
- Menactra®, Menomune®
- Where
- 20 sites in United States
- Volunteers
- 763 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company